Replies to post #5922 on CV Sciences Inc (CVSI)

[Det_Robert_Thorne]

Thanks, Marty. Just used MS Paint for chart

I've used Visio in the past, but the image in that post was just an an Alt-PrintScreen capture pasted into MS Paint, cropped, and then annotated using the fairly primitive but adequate tools in that program.

The problem with the CBD space is that its fairly easy to enter if you can afford a CO2 extractor and a biochemist.

CVSI was an early entry, and perhaps if it hadn't initially partnered with Medical Marijuana, Inc, which IMO has really bad corporate governance and has screwed-up nearly every business arrangement it has ever made, it might have been able to get a better start and not have to build its own sales organization starting in late 2014.

Now it has a lot of competition from companies like Endoca, Bluebird Botanicals, Isodiol, etc, and I think there might be a company or two in South or Central America. There are even some "Mom & Pop" CBD manufacturers in states where the growing of industrial hemp for "research" purposes is permitted by state law.

That's probably why the company changed its business focus, as announced in the January 4, 2016 PR announcing the acquisition of CanX and the name change from CannaVest to CV Sciences:

Mr. Mona continued, "This acquisition will allow us to leverage our expertise and reposition the Company to focus primarily on drug development, but also to continue our market leadership as a consumer products based company.

http://www.otcmarkets.com/stock/CVSI/news/CannaVest-Corp--Acquires-CanX--Inc--and-Its-Subsidiary-Canabine--LLC--Announces-Name-Change-and-Appointment-of-New-Director?id=122480&b=y

Of course, drug development is costly, and they're not generating the funds from sales, so more convertible notes are issued.